Sangamo Therapeutics Announces Presentations at 2021 Annual Meeting of the American Society of Gene & Cell Therapy
April 27 2021 - 4:30PM
Business Wire
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine
company, today announced upcoming data presentations at the 24th
Annual Meeting of the American Society of Gene & Cell Therapy
(ASGCT) being held May 11-14, 2021, in a virtual format.
“Our zinc finger technology has shown the versatility to have
broad applications across a diverse range of therapeutic areas and
the upcoming presentations at ASGCT will focus on one area of
particularly high unmet need: neurodegenerative diseases,” said
Jason Fontenot, Ph.D., Chief Scientific Officer at Sangamo. “These
abstracts show the potential of zinc finger protein transcription
factors to modulate expression of targeted genes in ALS and
Parkinson’s disease. We are encouraged that these early results
demonstrate the specificity, potency and potential of our
transcriptional regulation technology as an impactful genomic
medicine approach for these difficult-to-treat conditions. We look
forward to continuing our research.”
ASGCT Annual Meeting Presentations:
- Selective repression of C9ORF72 repeat expansion-containing
sense and antisense transcripts for the treatment of amyotrophic
lateral sclerosis (ALS) – Abstract #577 Poster Presentation –
Tuesday, May 11; 8:00-10:00 a.m. ET
- Alpha-synuclein repression using zinc finger protein
transcription factors – a novel therapeutic approach for the
treatment of Parkinson’s disease – Abstract #539 Poster
Presentation – Tuesday, May 11; 8:00-10:00 a.m. ET
All abstracts for the ASGCT Annual Meeting are available on
ASGCT’s website.
About Sangamo Therapeutics
Sangamo Therapeutics is committed to translating ground-breaking
science into genomic medicines with the potential to transform
patients’ lives using gene therapy, cell therapy, and genome
engineering. For more information about Sangamo, visit
www.sangamo.com.
Forward-Looking Statements
This press release contains forward-looking statements based on
our current expectations. These forward-looking statements include,
without limitation, statements relating to the potential to use
zinc finger technology, including zinc finger protein transcription
factors, to develop safe, effective and durable therapies. These
statements are not guarantees of future performance and are subject
to certain risks and uncertainties that are difficult to predict.
Our actual results may differ materially and adversely from those
expressed. Factors that could cause actual results to differ
include, but are not limited to, the research development process,
including the results of clinical trials; the unpredictable
regulatory approval process for product candidates; the
manufacturing of products and product candidates; the
commercialization of approved products; and the potential for
technological developments that obviate technologies used by
Sangamo. There can be no assurance that we will be able to develop
and obtain the necessary regulatory approvals for commercially
viable products. These risks and uncertainties are described more
fully in our Annual Report on Form 10-K for the year ended December
31, 2020 as filed with the Securities and Exchange Commission.
Forward-looking statements contained in this announcement are made
as of this date, and we undertake no duty to update such
information except as required under applicable laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210427006019/en/
Investor Relations & Media
Inquiries Aron Feingold 628.252.7494
afeingold@sangamo.com
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Apr 2023 to Apr 2024